Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced that its management will participate in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced that its management will participate in two upcoming investor conferences. The company will join the Jefferies Global Healthcare Conference for a fireside chat on June 6 at 10:30 a.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference for a fireside chat on June 12 at 3:20 p.m. ET. These events will be live-streamed and archived on Avadel's Investor Relations website for 90 days post-conference.
Positive
- Participation in high-profile investor conferences can increase visibility and investor interest.
- Live webcasts and archived recordings provide ongoing access to company information for investors.
Negative
- There are no new financial or clinical data disclosed in the announcement.
- The announcement does not provide any detailed updates on business development or pipeline progress.
- Lack of specific milestones or targets may not spark significant investor enthusiasm.
Details
News Market Reaction – AVDL
The recorded move for AVDL in the trading session of this news was +1.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
- Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 6 at 10:30 a.m. ET.
- Goldman Sachs 45th Annual Global Healthcare Conference: Fireside chat on Wednesday, June 12 at 3:20 p.m. ET.
A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Courtney Mogerley
Precision AQ
Courtney.Mogerley@precisionAQ.com
(212) 698-8687
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.